Save the date for a virtual R&D day with Cybin’s leadership team who will provide a progress update on the Company’s lead clinical programs CYB003 and CYB004 being developed as psychedelic-based therapies for the treatment of various mental health conditions.

CYB003, Cybin’s deuterated psilocybin analog, is currently being evaluated in a Phase 1/2a clinical trial for the treatment of major depressive disorder.  CYB003 is the first ever psilocybin analog to enter clinical development. During the event, management plans to provide an overview of the CYB003 program, including an interim readout from the ongoing trial and discuss future development plans.

CYB004 is a proprietary deuterated N,N-dimethyltryptamine (DMT) molecule being evaluated for the treatment of generalized anxiety disorder.  Cybin is currently conducting a Phase 1 exploratory trial (“CYB004-E trial”) evaluating IV DMT to yield essential safety and dosing optimization data for the future clinical development of CYB004 and will provide an update on its CYB004 program during the event.

A live Q&A session will follow the formal presentations.